Trial Profile
A Phase IIb trial of PXT864 for Alzheimer's Disease
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2017
Price :
$35
*
At a glance
- Drugs Acamprosate/baclofen (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 26 Apr 2017 According to a Pharnext media release, this company expects to launch this trial in 2017.
- 04 Apr 2017 New trial record